Sandoz' Biosimilar Etanercept On Its Way To EU Market
This article was originally published in Scrip
The EMA has accepted for review a biosimilar etanercept product from Novartis's Sandoz division. The biosimilar version of Pfizer's TNF-inhibitor Enbrel has been filed for use in all the indications detailed in Enbrel's label, including rheumatoid arthritis and psoriasis.
Register for our free email digests: